• 1
    Wang J, Loberg R, Taichman RS 2006 The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25: 573587.
  • 2
    Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM 2007 Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109: 27082717.
  • 3
    Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Van de Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K 2006 The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91: 605612.
  • 4
    Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T 1996 Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382: 635638.
  • 5
    Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P 2005 Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 36: 840853.
  • 6
    Zhang H, Hwang ST, Khanna C, Helman LJ 2008 Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25: 201211.
  • 7
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P 2003 Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18: 14041418.
  • 8
    Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, Bik To L, Fujii N, O'Loughlin PD, Evdokiou A, Zannettino AC 2009 Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 24: 11501161.
  • 9
    Peng SB, Peek V, Zhai Y, Paul DC, Lou Q, Xia X, Eessalu T, Kohn W, Tang S 2005 Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res 3: 227236.
  • 10
    Trentin L, Miorin M, Facco M, Baesso I, Carraro S, Cabrelle A, Maschio N, Bortoli M, Binotto G, Piazza F, Adami F, Zambello R, Agostini C, Semenzato G 2007 Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 138: 594602.
  • 11
    Möller C, Strömberg T, Juremalm M, Nilsson K, Nilsson G 2003 Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17: 203210.
  • 12
    Wendt MK, Cooper AN, Dwinell MB 2008 Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 27: 14611471.
  • 13
    Oliveira AM, Maria DA, Metzger M, Linardi C, Giorgi RR, Moura F, Martinez GA, Bydlowski SP, Novak EM 2009 Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 33: 470473.
  • 14
    Sordillo EM, Pearse RN 2003 RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 97 (3 Suppl): 802812.
  • 15
    Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, Dunstan CR 2007 Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40: 471478.
  • 16
    Zheng Y, Zhou H, Modzelewski JR, Kalak R, Blair JM, Seibel MJ, Dunstan CR 2007 Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 67: 95429548.
  • 17
    Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 104: 24842491.
  • 18
    Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K 2007 Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 121: 18571861.
  • 19
    Kingsley LA, Fournier PG, Chirgwin JM, Guise TA 2007 Molecular biology of bone metastasis. Mol Cancer Ther 6: 26092617.
  • 20
    Hirbe AC, Rubin J, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN 2007 Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA 104: 1406214067.